Patents by Inventor Matthew Lamm

Matthew Lamm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
    Patent number: 10842751
    Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 24, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Santipharp Panmai, Aditya Tatavarti, Andrew M. Farrington, Varsha Biyyala, Leonardo R. Allain, Marcela Nefliu, Gerard R. Klinzing, Jie Ren, Matthew Lamm
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE
    Publication number: 20200179291
    Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Santipharp Panmai, Aditya Tatavarti, Andrew M. Farrington, Varsha Biyyala, Leonardo R. Allain, Marcela Nefliu, Gerard R. Klinzing, Jie Ren, Matthew Lamm
  • Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
    Patent number: 10603282
    Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 31, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Santipharp Panmai, Aditya Tatavarti, Andrew M. Farrington, Varsha Biyyala, Leonardo R. Allain, Marcela Nefliu, Gerard R. Klinzing, Jie Ren, Matthew Lamm
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE
    Publication number: 20190254977
    Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Application
    Filed: November 29, 2016
    Publication date: August 22, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Santipharp Panmai, Aditya Tatavarti, Andrew M. Farrington, Varsha Biyyala, Leonardo R. Allain, Marcela Nefliu, Gerard R. Klinzing, Jie Ren, Matthew Lamm
  • Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
    Patent number: 9604971
    Abstract: This invention relates to a co-crystal of vorapaxar and aspirin. The inventive co-crystal antagonizes the PAR-1 receptor. This invention also provides for pharmaceutical compositions comprising the inventive co-crystal as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by antagonizing the PAR-1 receptor.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: March 28, 2017
    Assignee: ARALEZ PHARMACEUTICALS TRADING DAC
    Inventors: Scott Trzaska, Alicia V. Duran-Capece, Matthew Lamm
  • CO-CRYSTAL OF THE PAR-1 RECEPTOR ANTAGONISTS VORAPAXAR AND ASPRIN
    Publication number: 20160159779
    Abstract: This invention relates to a co-crystal of vorapaxar and aspirin. The inventive co-crystal antagonizes the PAR-1 receptor. This invention also provides for pharmaceutical compositions comprising the inventive co-crystal as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by antagonizing the PAR-1 receptor.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 9, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott Trzaska, Alicia V. Duran-Capece, Matthew Lamm